• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA ® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck ' s Supplemental New Drug Applications for ZETIA ® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: English ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news